Sinobioway Medicine(002581)2025-01-24 10:10Financial Performance Expectations - The company expects a net loss for 2024 between 95 million and 155 million CNY, compared to a net loss of 332.45 million CNY in the same period last year[3]. - The expected net profit after deducting non-recurring gains and losses is projected to be a loss between 93.27 million and 153.27 million CNY, compared to a loss of 317.57 million CNY last year[3]. - The expected basic earnings per share is projected to be a loss between 0.1440 and 0.2349 CNY per share, compared to a loss of 0.5039 CNY per share last year[3]. - The anticipated operating revenue for 2024 is between 360 million and 400 million CNY, down from 429.79 million CNY in the previous year[3]. Impairment Provisions - The company plans to recognize impairment provisions for long-term assets, accounts receivable, and inventory, totaling between 90 million and 115 million CNY[6]. - The final impairment amounts will be determined after evaluation and audit by qualified assessment and auditing institutions[6]. Factors Affecting Performance - The decline in performance is attributed to external environment factors and industry policies affecting the main business revenue[5]. Marketing and Product Development - The company is actively engaged in marketing and market exploration efforts, focusing on expanding its new product layout[5]. Financial Data Caution - The financial data in the earnings forecast has not been audited by the accounting firm[4]. - Investors are advised to make cautious decisions as the financial data is preliminary and subject to change in the 2024 annual report[7].